Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026Post-ROSC workup: Evaluate like nonathletes — interpret like athletes QTc often prolonged post-arrest → reassess 3–5 days Echo may miss apical HCM/ARVC → CMR CCTA = for anomalous coronaries LGE on CMR: fibrosis ~38% of healthy athletes → avoid overcalling pathology 000 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026Emergency Action Plans (EAPs) Secondary prevention = survival Treat collapse + unresponsiveness as SCA → AED on immediately Target: collapse-to-shock <3 minutes Recent survival reports: ~48% to 89% EMS activation • CPR • Early defib • AED maintenance • Team rehearsal 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026Screening: H&P vs ECG H&P alone: low sensitivity + high false positives ECG: detects ~2/3 of lethal disorders (with modern athlete-ECG criteria) Meta-analysis (47,137 athletes): WPW: 1 / 703 HCM: 1 / 2613 LQTS: 1 / 2613 Practical: ECG improves detection efficiency. 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026Etiology (modern autopsy series, 11–39y) What causes SCD in young athletes? Approx. distribution: Autopsy-negative SUD: ~19% HCM: ~13% Coronary anomalies: ~11% ACM: ~10% CAD: ~8% Myocarditis-related: ~6% Aortic dissection: ~4% WPW: ~3% Note: ≥25y → CAD dominates. 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026Disparities (sex-race) Risk is not evenly distributed Male athletes: 1/35,000–83,000 Female athletes: 1/93,000–323,000 College athletes: Black: 1/18,000 athlete-years White: 1/39,000 athlete-years HS survival after SCA: 51% (underrepresented groups) vs 76% (nonHispanic White) 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026How often does SCA/SCD occur? Prepubertal: ~1 / 500,000 athlete-years Adolescents (13–17): 1 / 66,000–88,000 College athletes: 1 / 51,000–67,000 Bottom line: risk rises with age + ascertainment. 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 20/01/2026Sudden Cardiac Arrest in Athletes (SCA) ❤️What cardiologists should know (NEJM 2026) Rare • High-impact • Preventable outcomes Key takeaways: Incidence varies • Causes differ by age • EAPs save lives • RTP is evolving Link: www.nejm.org/doi/pdf/10.1... @NEJM 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/2025@drmarthagulati.bsky.social @vineetaojha.bsky.social @vassv.bsky.social @accintouch.bsky.social @annakatebarton.bsky.social @escardio.bsky.social @cvprevention.medsky.social @worldheart.org @jgrapsa.bsky.social @katehanneman.bsky.social @ijcvimaging.bsky.social 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20259️⃣ genetics! 💥 some genetic mutation are at higher risk than others and need closer follow-up 000 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20258️⃣ cardiovascular imaging reccomandation #exhofisrt #whyCMR #yesCCT Here 👇 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20257️⃣ For women with mechanical heart valves—anticoagulation regimens must be carefully managed, including switching between VKAs, LMWH, and UFH depending on the pregnancy stage and timing of delivery. ⏱" 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20256️⃣Planning mode of delivery? These guidelines advise against C-section when not medically necessary— vaginal delivery remains first choice, unless specific cardiovascular conditions warrant otherwise. 👶" 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20255️⃣ Physiological changes during pregnancy are profound—stroke volume and cardiac output increase by 30–50%, and heart rate by 10–20 bpm. These changes can stress an already compromised heart. 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20254️⃣ Pregnancy in women with CVD must include shared decision-making, considering genetic background, obstetric history, comorbidities, lifestyle, and values—not just clinical risk. 🤰❤️" 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20253️⃣ Pregnancy with cardiovascular disease now involves a multidisciplinary Pregnancy Heart Team—specialized care before, during, and after pregnancy leads to fewer maternal deaths and better outcomes. 💪 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/20252️⃣ No more blanket “pregnancy forbidden” policies—for high-risk conditions (like PAH or vascular Ehlers-Danlos), the focus shifts to counselling by a multidisciplinary Pregnancy Heart Team, empowering informed choices. 🏥 100 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/08/2025 ESC Guidelines on Cardio-Pregnancy (2025) Here my highlights 👇 1⃣ personalized risk assessment for all women with cardiovascular disease considering pregnancy. Shared decision-making is at the heart of the approach🤝 210 0
Reposted by Anna Giulia Pavon Dr Martha Gulati @drmarthagulati.bsky.social · 08/03/2025Happy International Women’s Day to all the amazing women in this world! #AccelerateAction #InternationalWomenDay #BreakingBarriers #CardioSky 1298 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 04/02/2025academic.oup.com/ehjcimaging/...academic.oup.comA very late intracardiac myxoid liposarcoma metastasisAn 81-year-old male patient, known for a previous inferior myocardial infarction, underwent a regular outpatient cardiac follow-up visit. Past medical hist 000 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 04/02/2025@antjehellwich.bsky.social @annakatebarton.bsky.social @chriskramermd.bsky.social @glaucomflecken.bsky.social @saraersozlu.bsky.social @escardio.bsky.social @jgrapsa.bsky.social @katehanneman.bsky.social @nmerke.bsky.social @womenasone.bsky.social @purviparwani.bsky.social 010 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 04/02/2025Presented at #scmr2025 published in #EHJCVI unexpected finding at #echofirst 1️⃣MMI in cardiac mass is the key 2️⃣Refers to common mass characteristics but.. 3️⃣Always consider patient's anamnesis 👇 What is this cardiac mass? @vassv.bsky.social @vicferrarimdbs.bsky.social @vineetaojha.bsky.social 4103 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 03/02/2025@drmarthagulati.bsky.social @purviparwani.bsky.social @vineetaojha.bsky.social @saraersozlu.bsky.social @annakatebarton.bsky.social @glaucomflecken.bsky.social 010 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 03/02/2025Among the all talks at #scmr25 i was particularly touched by @ElsieRadiology talk: 1️⃣Find Joy+meaning of ur work 2️⃣Find your people 3️⃣Take initiative 4️⃣Establish a personalized work-life balance 5️⃣Be patient to yourself Growth comes from experience:learn, evolve, and rise! 152 0
Reposted by Anna Giulia Pavon Sara Ersözlü, MD @saraersozlu.bsky.social · 30/01/2025Honored to co-moderate the Rapid-Fire Session on Arrhythmias II tomorrow at 5:30 PM in Blue Room Pre-Function Kiosk 1 with my wonderful co-moderator @annagiuliapavon.bsky.social And right after, join us for the Welcome Reception, where the amazing SCMR Band 5T will be performing! @scmr #SCMR2025 154 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/01/2025@vineetaojha.bsky.social @vassv.bsky.social @purviparwani.bsky.social @saraersozlu.bsky.social @rishabhkhurana.bsky.social @doctiger.bsky.social @jasonnjohnson.bsky.social @annagiuliapavon.bsky.social @alex-kallifatidis.bsky.social @amroalsaid.bsky.social @drjenniferco-vu.bsky.social 000 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 30/01/2025#SCMR2025 Happy to start the 2nd day on #whyCMR discussion cardiac masses! 🏠Kiosk 1 - blue room ⏰8-9 AM 👉Many tips and tricks for patients diagnosis and management 👉Learn from cases is essential! 🧲See u there! 111 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 28/01/2025#SCMR2025 Ready for the biggest #whyCMR meeting! 📢Quick start tomorrow with clinician preconference 🪙Part of level 1 course! 👉 More info on Eventscribe app 👀 Look for the new insights on quant perf and valvular heart disease @vineetaojha.bsky.social @scmrorg.bsky.social @saraersozlu.bsky.social 034 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 26/01/2025@shehabanwer.bsky.social @vineetaojha.bsky.social @escardio.bsky.social @jgrapsa.bsky.social 000 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 26/01/2025👉#whyCMR in Mitral regurgitation! Significant strides in cardiovascular imaging: 'The relationship between symptoms and regurgitant severity in primary mitral regurgitation: a CMR study.' by @seth_uretsky Explore in #IJCVI! 👇 doi.org/10.1007/s10554…doi.org 132 0
Reposted by Anna Giulia Pavon vineetaojha.bsky.social @vineetaojha.bsky.social · 25/01/2025🎤🎤🎤🎤Just 4 days to go for @scmrorg.bsky.social annual meeting #SCMR2025- there is still chance to register for the largest #whyCMR meeting, you can attend virtually. For updates, follow the social media ambassadors⬇️ @purviparwani.bsky.social @saraersozlu.bsky.social @annagiuliapavon.bsky.social 199 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025@vineetaojha.bsky.social @mri-cprieto.bsky.social @scmrorg.bsky.social @chiarabd.bsky.social @purviparwani.bsky.social 000 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025😱Cardiac mass are always a challenge! 27yo F with apical cardiac mass, stabile in years Benign nature according to Bologna CMR mass score: pubmed.ncbi.nlm.nih.gov/38502734/ #whyCMR Any clues on what it is? #SCMR2025 If you need more experience: 👍More cases discussion at #SCMR2025 #whyCMR 142 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025@vineetaojha.bsky.social @purviparwani.bsky.social @jgrapsa.bsky.social @scmrorg.bsky.social @saraersozlu.bsky.social @doctiger.bsky.social @chiarabd.bsky.social 010 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025Bibliography: - Cardiac Magnetic Resonance to Predict Cardiac Mass Malignancy: The CMR Mass Score doi: 10.1161/CIRCIMAGING.123.016115 - How to evaluate cardiac masses by cardiovascular magnetic resonance parametric mapping? doi.org/10.1093/ehjc...doi.orgHow to evaluate cardiac masses by cardiovascular magnetic resonance parametric mapping?Cardiac masses represent a heterogenous groups of primary and secondary cardiac tumours, benign and malignant masses, and tumour-like lesions. About 75% of 111 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025Mind that: - Bologna CMR mass score may help you ( ≥5 predicted a higher risk of all-cause death) - a multimodality imaging approach is always the key in many situations! -T1 mapping and T2 mapping may add some important information too 120 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025LGE: 👀 pattern: homogeneous vs heterogeneous Intense: fibroma Heterogeneous: myxoma - Hemangioma - hamartoma - paraganglioma - most malignant masses 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025Tissue Characterisation: T2FSE 👉 hypointense - isointense or hyperintense? 😆 fluid is bright! 💡hyper: myxoma - lipoma -hemangioma - hamartoma -cyst - recent hemorr - metastases - sarcoma 💡iso: fibroelastoma- lymphoma 💡hypo: thrombus - fibroma- calcification - melanoma 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025Tissue Characterisation: T1FSE 👉 hypointense - isointense or hyperintense? 😆 fat is bright! 💡hyper: lipoma -recent hemorrhage - melanoma 💡iso: myxoma - fibroelastoma- hemangioma-hamartoma - fibroma - sarcoma 💡hypo: thrombus - cyst - calcification - metastases 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025Tissue Characterisation: Mass perfusion ❤️ First-pass perfusion after gadolinium with slices through the mass to assess vascularity 👀 highly vascularized lesions are bright! 💡malignancy - hemangioma - hamartoma - paraganglioma - angiosarcoma - rhabdomyosarcoma 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025More often Malignant: 😱Poorly defined - Intramyocardial - multiple lesions - inhomogenous with central necrosis - pericardial effusion - invasive growth More often bening: 🍀well defined - intracavitary - mobile - stalk 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025CINE IMAGES: mind the infiltration! ‼️disruption of neighboring tissue 👉extension of the mass across the pericardium into myocardium, interruption of epicardial/endocardial contours 👀increased thickness - hypo/dys/akinesia of a focal myocardial area (of no ischemic etiology) 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025CINE IMAGES: SSFP 👉 should cover all 🧡 chambers to study LV adn RV EF - volumes 👉 need to explore the CM and its features mass location - site of attachment - morphology 👀 pericardium: effusion? 110 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025Imaging Protocol: 1. bSSFP cine imaging 2. T1-w FSE 3. T2-wFSE 4. First-pass perfusion 5. LGE Other: EGE - T1 map - T2 map 120 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 23/01/2025👉Cardiac Mass: a small #whyCMR Tweetorial ‼️histology remains the gold standard for the definite diagnosis of malignancy 🧲frequently evaluated by #whyCMR 👀 Here a recap + some tips and tricks! 🧡 please complete the discussion or add some useful bibliography in comments 274 0
Anna Giulia Pavon @annagiuliapavon.bsky.social · 22/01/2025Almost ready for the biggest meeting on #whyCMR: #scmr25 Still a bit of time to register left! lots of activities ready for Early career 👀Mentorship program!! Here the link: 2025scmr.eventscribe.net/agenda.asp?p... @vassv.bsky.social @vineetaojha.bsky.social @purviparwani.bsky.social 062 0